Sanofi recalls painkiller in India

Sanofi
Pills

Indian drugmakers have often found themselves in the sights of Western regulators who have instructed them to fix plants and recall products. Now in a turnabout, one of India’s drug regulators is having Sanofi recall a painkiller it says did not meet specifications.

Sanofi has recalled four batches of Combiflam after India’s Central Drugs Standard Control Organisation (CDSCO) found it was not meeting specifications for disintegration, Reuters reports. Combiflam, a combo of paracetamol and ibuprofen, is one of the French drugmaker’s top sellers in the country, the news service reports.

A Sanofi spokeswoman told DNA India that while there was no safety issue with the drug, it was being recalled since the CDSCO had deemed it substandard. "We have acted immediately and completed the recall for two batches, while the recall of the remaining two batches is ongoing," she said, adding that the company has already taken steps to rectify the problem.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Indian drugmakers have often found their products the subjects of recalls in the U.S. Wockhardt recalled more than 7 million products last year after several of its plants came under fire by the FDA. Just this week, Indian companies Dr. Reddy’s Laboratories ($RDY) and Akorn ($AKRX) both had recalls listed by the FDA. But so did U.S. drugmakers Mylan ($MYL) and Pfizer’s ($PFE) Hospira.

- read the Reuters story 
- get more from DNA India

Related Articles: 
India's Wockhardt recalls millions of packages of drugs in sweeping recall 
Dr. Reddy's recalls drugs that failed impurities test

Read more on

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.